SUFU white paper on overactive bladder anticholinergic medications and dementia risk

Aims Anticholinergic medications are widely used in the treatment of overactive bladder (OAB), as well as for short‐term treatment of bladder symptoms following a variety of urologic surgeries. Mounting evidence points to an association between anticholinergic medications and the increased risk of i...

Full description

Saved in:
Bibliographic Details
Published in:Neurourology and urodynamics 2022-11, Vol.41 (8), p.1928-1933
Main Authors: Zillioux, Jacqueline, Welk, Blayne, Suskind, Anne M., Gormley, E. Ann, Goldman, Howard B.
Format: Article
Language:English
Subjects:
anticholinergic
Anticholinergics
antimuscarinic
Bladder
Botulinum toxin
Cholinergic Antagonists - adverse effects
Chronic exposure
Cognitive ability
cognitive impairment
Dementia
Dementia - chemically induced
Dementia disorders
Female
Humans
Literature reviews
Neuromodulation
overactive bladder
Patients
Quality of Life
Repressor Proteins - therapeutic use
urgency incontinence
Urinary Bladder, Overactive - therapy
Urodynamics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Anticholinergic medications are widely used in the treatment of overactive bladder (OAB), as well as for short‐term treatment of bladder symptoms following a variety of urologic surgeries. Mounting evidence points to an association between anticholinergic medications and the increased risk of incident dementia. The Society for Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) thus convened a committee of subject experts to contextualize the current understanding of the cognitive risks of anticholinergic medications in the urologic patient population and to provide practical clinical guidance on this subject. Methods Statements are based on an expert literature review and the committee's opinion. The document has been reviewed and approved by the SUFU board. Results Chronic use (>3 months) of OAB anticholinergic medications is likely associated with an increased risk of new‐onset dementia. Short‐term (
ISSN:0733-2467
1520-6777
DOI:10.1002/nau.25037